
Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis – Drugs In Development, 2022, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.
Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 21, 12, 2, 35 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis – Drugs In Development, 2022, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.
Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 21, 12, 2, 35 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
226 Pages
- Introduction
- Global Markets Direct Report Coverage
- Glomerulonephritis – Overview
- Glomerulonephritis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glomerulonephritis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glomerulonephritis – Companies Involved in Therapeutics Development
- AKSO Biopharmaceutical Inc
- Alexion Pharmaceuticals Inc
- Algomedix Inc
- Alnylam Pharmaceuticals Inc
- Amyndas Pharmaceuticals LLC
- Anagenics Ltd
- Angion Biomedica Corp
- Apellis Pharmaceuticals Inc
- Argenx SE
- Arrowhead Pharmaceuticals Inc
- Bayer AG
- BioCryst Pharmaceuticals Inc
- Biogen Inc
- Boehringer Ingelheim International GmbH
- Cabaletta Bio Inc
- Calliditas Therapeutics AB
- Ceptur Therapeutics Inc
- Certa Therapeutics Pty Ltd
- ChemoCentryx Inc
- Chinook Therapeutics Inc
- Coegin Pharma AS
- Cytodesign Inc
- Delta 4 GmbH
- DiaMedica Therapeutics Inc
- Dimerix Ltd
- Eledon Pharmaceuticals Inc
- Eli Lilly and Co
- Ergon Pharmaceuticals LLC
- Generian Pharmaceuticals Inc
- Goldfinch Bio Inc
- HanAll Biopharma Co Ltd
- Horizon Therapeutics Plc
- IGAN Biosciences Inc
- ImmunoWork LLC
- Inmagene Biopharmaceuticals Ltd
- InSilico Medicine
- Integral Molecular Inc
- INVENT Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Jiangsu Hengrui Medicine Co Ltd
- KeyMed Biosciences Inc
- Mallinckrodt Plc
- MorphoSys AG
- Novartis AG
- NovelMed Therapeutics Inc
- Oak Hill Bio Inc
- Omeros Corp
- Oraxion Therapeutics Inc
- Pfizer Inc
- PlateletBio
- Polyneuron Pharmaceuticals AG
- Puretech Health Plc
- Ra Pharmaceuticals Inc
- Reata Pharmaceuticals Inc
- RemeGen Co Ltd
- River 3 Renal Corp
- Rohto Pharmaceutical Co Ltd
- Shanghai Alebund Pharmaceuticals Ltd
- Shenzhen Evergreen Therapeutics Co Ltd
- Slate Bio Inc
- Sujana Biotech, LLC
- Surrozen Inc
- Takeda Pharmaceutical Co Ltd
- Transcenta Holding Ltd
- Travere Therapeutics Inc
- Vera Therapeutics Inc
- Vertex Pharmaceuticals Inc
- Visterra Inc
- Wuhan LL Science and Technology Development Co Ltd
- ZyVersa Therapeutics Inc
- Glomerulonephritis – Drug Profiles
- AB-001 – Drug Profile
- ADR-001 – Drug Profile
- ALXN-2050 – Drug Profile
- AMY-101 – Drug Profile
- ANG-3070 – Drug Profile
- AP-305 – Drug Profile
- AROC-3 – Drug Profile
- atacicept – Drug Profile
- atrasentan hydrochloride – Drug Profile
- avacopan – Drug Profile
- AVX-002 – Drug Profile
- bardoxolone methyl – Drug Profile
- baricitinib – Drug Profile
- batoclimab – Drug Profile
- BaxB-01 – Drug Profile
- BCX-9930 – Drug Profile
- BI-764198 – Drug Profile
- BION-1301 – Drug Profile
- Bispecific Monoclonal Antibody for Focal Segmental Glomerulosclerosis and Polycystic Kidney Disease – Drug Profile
- budesonide DR – Drug Profile
- CAB-101 – Drug Profile
- CAB-102 – Drug Profile
- CCX-872 – Drug Profile
- cemdisiran – Drug Profile
- CM-338 – Drug Profile
- corticotropin – Drug Profile
- danicopan – Drug Profile
- dazodalibep – Drug Profile
- deupirfenidone – Drug Profile
- DM-199 – Drug Profile
- Drug for Focal Segmental Glomerulosclerosis (FSGS) – Drug Profile
- Drug for Glomerulonephritis – Drug Profile
- Drugs for IgA Nephropathy, Lupus Nephritis, Polycystic Kidney Disease – Drug Profile
- Drugs to Antagonize Endothelin 1 Receptor for Focal Segmental Glomerulosclerosis (FSGS) and Kidney Disease – Drug Profile
- efgartigimod alfa – Drug Profile
- EG-102 – Drug Profile
- ERG-240 – Drug Profile
- felzartamab – Drug Profile
- finerenone – Drug Profile
- FT-011 – Drug Profile
- Gene-Modified Cell therapy for Membranous Glomerulonephritis – Drug Profile
- GFB-024 – Drug Profile
- GFB-8438 – Drug Profile
- GFB-887 – Drug Profile
- HR-19042 – Drug Profile
- IC-100 – Drug Profile
- IgA nephropathy (IgAN) – Drug Profile
- IL-233 – Drug Profile
- IMG-025 – Drug Profile
- inaxaplin – Drug Profile
- INV-100 – Drug Profile
- IONIS-FB-LRx – Drug Profile
- iptacopan hydrochloride – Drug Profile
- ISM004-1057D – Drug Profile
- mezagitamab – Drug Profile
- Monoclonal Antibodies to Inhibit ITGAM for Glomerulonephritis, Inflammation, Multiple Sclerosis, Thrombosis and Vascular Disorders – Drug Profile
- Monoclonal Antibody to Antagonize IL2R for Immunology and Genito Urinary System – Drug Profile
- Monoclonal Antibody to Inhibit CFD for C3 Glomerulonephritis – Drug Profile
- MY-008 – Drug Profile
- narsoplimab – Drug Profile
- NM-8074 – Drug Profile
- ORX-301 – Drug Profile
- P2X7 Antibody – Drug Profile
- pegcetacoplan – Drug Profile
- PF-06730512 – Drug Profile
- PF-1355 – Drug Profile
- PLA2R-CAART – Drug Profile
- Polymer for IgA Nephropathy – Drug Profile
- Primary Membranous Nephropathy – Drug Profile
- propagermanium – Drug Profile
- QR-059 – Drug Profile
- QR-060 – Drug Profile
- QR-060127 – Drug Profile
- R-3R01 – Drug Profile
- ravulizumab LA – Drug Profile
- Recombinant Enzyme for IgA Nephropathy – Drug Profile
- Recombinant Enzyme to Inhibit C3B and C4B for IgA Nephropathy (Berger's Disease) – Drug Profile
- rituximab – Drug Profile
- SHR-2010 – Drug Profile
- Small Molecule to Block TRPC6 for Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, Hypertrophy Cardiomyopathy and Kidney Disease – Drug Profile
- Small Molecule to Inhibit APOL1 for Focal Segmental Glomerulosclerosis – Drug Profile
- Small Molecules to Activate AMPK for Glomerulonephritis, Polycystic Kidney Disease, Myotonic Dystrophy and Mitochondrial Diseases – Drug Profile
- Small Molecules to Inhibit Complement Factor D for Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy – Drug Profile
- Small Molecules to Inhibit MASP2 for Immunology – Drug Profile
- sparsentan – Drug Profile
- Synthetic Peptide for Glomerulonephritis – Drug Profile
- Synthetic Peptides to Inhibit Factor D for Geographic Atrophy, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease – Drug Profile
- tegoprubart – Drug Profile
- telitacicept – Drug Profile
- TM-5484 – Drug Profile
- TST-004 – Drug Profile
- Undisclosed Target 2 – Drug Profile
- Vaccine to Target CD40 for Membranous Glomerulonephritis – Drug Profile
- valziflocept – Drug Profile
- VAR-200 – Drug Profile
- VIS-649 – Drug Profile
- Glomerulonephritis – Dormant Projects
- Glomerulonephritis – Discontinued Products
- Glomerulonephritis – Product Development Milestones
- Featured News & Press Releases
- Jun 09, 2022: Alnylam reports positive topline results from phase 2 study of investigational cemdisiran for the treatment of IgA nephropathy
- Jun 06, 2022: Apellis and Sobi announce first patient dosed in phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, rare kidney diseases with high unmet medical need
- May 31, 2022: Significant milestone achieved with first patient recruited into DMX-200 phase 3 action3 FSGS kidney clinical trial
- May 22, 2022: Vera Therapeutics announces new atacicept phase 2 clinical data in two oral presentations at the 59th European Renal Association Congress
- May 20, 2022: Chinook Therapeutics presents data from atrasentan phase 2 AFFINITY IgA nephropathy (IgAN) patient cohort and Evotec collaboration at the 59th European Renal Association (ERA) Congress 2022
- May 19, 2022: Calliditas receives positive CHMP opinion in IgA nephropathy
- May 19, 2022: Chinook Therapeutics presents updated data from Atrasentan preclinical mechanism of action studies at the 59th European Renal Association (ERA) Congress 2022
- May 17, 2022: Travere Therapeutics announces presentations of abstracts at the 59th ERA Congress
- May 16, 2022: Travere Therapeutics announces FDA acceptance and priority review of new drug application for sparsentan for the treatment of IgA nephropathy
- May 12, 2022: Dimerix presents at Bioshares Biotech Summit
- May 09, 2022: FDA IND approval for the ACTION3 phase 3 clinical trial OF DMX-200 in FSGS
- May 09, 2022: Eledon Pharmaceuticals announces first patient dosed in phase 2a trial evaluating Tegoprubart in IgA Nephropathy
- May 03, 2022: Vera Therapeutics announces two oral presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress featuring new clinical data on atacicept in IgA nephropathy and in systemic lupus erythematosus
- Apr 05, 2022: Everest Medicines announces that topline results from Chinese subpopulation consistent with global phase 3 NefIgArd study part A analysis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Glomerulonephritis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Universities/Institutes, 2022
- Table 7: Products under Development by Companies, 2022
- Table 8: Products under Development by Companies, 2022 (Contd..1)
- Table 9: Products under Development by Companies, 2022 (Contd..2)
- Table 10: Products under Development by Companies, 2022 (Contd..3)
- Table 11: Products under Development by Companies, 2022 (Contd..4)
- Table 12: Products under Development by Companies, 2022 (Contd..5)
- Table 13: Products under Development by Companies, 2022 (Contd..6)
- Table 14: Products under Development by Universities/Institutes, 2022
- Table 15: Number of Products by Stage and Target, 2022
- Table 16: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 17: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 18: Number of Products by Stage and Mechanism of Action, 2022
- Table 19: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 20: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 21: Number of Products by Stage and Route of Administration, 2022
- Table 22: Number of Products by Stage and Molecule Type, 2022
- Table 23: Glomerulonephritis – Pipeline by AKSO Biopharmaceutical Inc, 2022
- Table 24: Glomerulonephritis – Pipeline by Alexion Pharmaceuticals Inc, 2022
- Table 25: Glomerulonephritis – Pipeline by Algomedix Inc, 2022
- Table 26: Glomerulonephritis – Pipeline by Alnylam Pharmaceuticals Inc, 2022
- Table 27: Glomerulonephritis – Pipeline by Amyndas Pharmaceuticals LLC, 2022
- Table 28: Glomerulonephritis – Pipeline by Anagenics Ltd, 2022
- Table 29: Glomerulonephritis – Pipeline by Angion Biomedica Corp, 2022
- Table 30: Glomerulonephritis – Pipeline by Apellis Pharmaceuticals Inc, 2022
- Table 31: Glomerulonephritis – Pipeline by Argenx SE, 2022
- Table 32: Glomerulonephritis – Pipeline by Arrowhead Pharmaceuticals Inc, 2022
- Table 33: Glomerulonephritis – Pipeline by Bayer AG, 2022
- Table 34: Glomerulonephritis – Pipeline by BioCryst Pharmaceuticals Inc, 2022
- Table 35: Glomerulonephritis – Pipeline by Biogen Inc, 2022
- Table 36: Glomerulonephritis – Pipeline by Boehringer Ingelheim International GmbH, 2022
- Table 37: Glomerulonephritis – Pipeline by Cabaletta Bio Inc, 2022
- Table 38: Glomerulonephritis – Pipeline by Calliditas Therapeutics AB, 2022
- Table 39: Glomerulonephritis – Pipeline by Ceptur Therapeutics Inc, 2022
- Table 40: Glomerulonephritis – Pipeline by Certa Therapeutics Pty Ltd, 2022
- Table 41: Glomerulonephritis – Pipeline by ChemoCentryx Inc, 2022
- Table 42: Glomerulonephritis – Pipeline by Chinook Therapeutics Inc, 2022
- Table 43: Glomerulonephritis – Pipeline by Coegin Pharma AS, 2022
- Table 44: Glomerulonephritis – Pipeline by Cytodesign Inc, 2022
- Table 45: Glomerulonephritis – Pipeline by Delta 4 GmbH, 2022
- Table 46: Glomerulonephritis – Pipeline by DiaMedica Therapeutics Inc, 2022
- Table 47: Glomerulonephritis – Pipeline by Dimerix Ltd, 2022
- Table 48: Glomerulonephritis – Pipeline by Eledon Pharmaceuticals Inc, 2022
- Table 49: Glomerulonephritis – Pipeline by Eli Lilly and Co, 2022
- Table 50: Glomerulonephritis – Pipeline by Ergon Pharmaceuticals LLC, 2022
- Table 51: Glomerulonephritis – Pipeline by Generian Pharmaceuticals Inc, 2022
- Table 52: Glomerulonephritis – Pipeline by Goldfinch Bio Inc, 2022
- Table 53: Glomerulonephritis – Pipeline by HanAll Biopharma Co Ltd, 2022
- Table 54: Glomerulonephritis – Pipeline by Horizon Therapeutics Plc, 2022
- Table 55: Glomerulonephritis – Pipeline by IGAN Biosciences Inc, 2022
- Table 56: Glomerulonephritis – Pipeline by ImmunoWork LLC, 2022
- Table 57: Glomerulonephritis – Pipeline by Inmagene Biopharmaceuticals Ltd, 2022
- Table 58: Glomerulonephritis – Pipeline by InSilico Medicine, 2022
- Table 59: Glomerulonephritis – Pipeline by Integral Molecular Inc, 2022
- Table 60: Glomerulonephritis – Pipeline by INVENT Pharmaceuticals Inc, 2022
- Table 61: Glomerulonephritis – Pipeline by Ionis Pharmaceuticals Inc, 2022
- Table 62: Glomerulonephritis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 63: Glomerulonephritis – Pipeline by KeyMed Biosciences Inc, 2022
- Table 64: Glomerulonephritis – Pipeline by Mallinckrodt Plc, 2022
- Table 65: Glomerulonephritis – Pipeline by MorphoSys AG, 2022
- Table 66: Glomerulonephritis – Pipeline by Novartis AG, 2022
- Table 67: Glomerulonephritis – Pipeline by NovelMed Therapeutics Inc, 2022
- Table 68: Glomerulonephritis – Pipeline by Oak Hill Bio Inc, 2022
- Table 69: Glomerulonephritis – Pipeline by Omeros Corp, 2022
- Table 70: Glomerulonephritis – Pipeline by Oraxion Therapeutics Inc, 2022
- Table 71: Glomerulonephritis – Pipeline by Pfizer Inc, 2022
- Table 72: Glomerulonephritis – Pipeline by PlateletBio, 2022
- Table 73: Glomerulonephritis – Pipeline by Polyneuron Pharmaceuticals AG, 2022
- Table 74: Glomerulonephritis – Pipeline by Puretech Health Plc, 2022
- Table 75: Glomerulonephritis – Pipeline by Ra Pharmaceuticals Inc, 2022
- Table 76: Glomerulonephritis – Pipeline by Reata Pharmaceuticals Inc, 2022
- Table 77: Glomerulonephritis – Pipeline by RemeGen Co Ltd, 2022
- Table 78: Glomerulonephritis – Pipeline by River 3 Renal Corp, 2022
- Table 79: Glomerulonephritis – Pipeline by Rohto Pharmaceutical Co Ltd, 2022
- Table 80: Glomerulonephritis – Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022
- Table 81: Glomerulonephritis – Pipeline by Shenzhen Evergreen Therapeutics Co Ltd, 2022
- Table 82: Glomerulonephritis – Pipeline by Slate Bio Inc, 2022
- Table 83: Glomerulonephritis – Pipeline by Sujana Biotech, LLC, 2022
- Table 84: Glomerulonephritis – Pipeline by Surrozen Inc, 2022
- Table 85: Glomerulonephritis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 86: Glomerulonephritis – Pipeline by Transcenta Holding Ltd, 2022
- Table 87: Glomerulonephritis – Pipeline by Travere Therapeutics Inc, 2022
- Table 88: Glomerulonephritis – Pipeline by Vera Therapeutics Inc, 2022
- Table 89: Glomerulonephritis – Pipeline by Vertex Pharmaceuticals Inc, 2022
- Table 90: Glomerulonephritis – Pipeline by Visterra Inc, 2022
- Table 91: Glomerulonephritis – Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022
- Table 92: Glomerulonephritis – Pipeline by ZyVersa Therapeutics Inc, 2022
- Table 93: Glomerulonephritis – Dormant Projects, 2022
- Table 94: Glomerulonephritis – Dormant Projects, 2022 (Contd..2)
- Table 95: Glomerulonephritis – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Glomerulonephritis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Top 10 Molecule Types, 2022
- Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.